Tag Archive for: ARPA-H

Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HHS in the US is moving in a different direction?